Ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
encephalopathy	encephalopathy	O	DISEASE	OTHERS	I
presenting	presenting	O	O	O	O
with	with	O	O	O	O
asterixis	asterixis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

CNS	cns	O	O	O	O
toxic	toxic	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
antineoplastic	antineoplastic	O	O	O	O
agent	agent	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
IFX	ifx	O	O	OTHERS	I
)	)	O	O	O	O
are	are	O	O	O	O
frequent	frequent	O	O	O	O
and	and	O	O	O	O
include	include	O	O	O	O
a	a	O	O	O	O
variety	variety	O	O	O	O
of	of	O	O	O	O
neurological	neurological	O	O	OTHERS	I
symptoms	symptoms	O	O	OTHERS	I
that	that	O	O	O	O
can	can	O	O	O	O
limit	limit	O	O	O	O
drug	drug	O	O	O	O
use	use	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
a	a	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
51-year-old	51-year-old	O	O	O	O
man	man	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
severe	severe	O	O	O	O
,	,	O	O	O	O
disabling	disabling	O	O	O	O
negative	negative	O	O	O	O
myoclonus	myoclonus	O	DISEASE	OTHERS	I
of	of	O	O	O	O
the	the	O	O	O	O
upper	upper	O	O	O	O
and	and	O	O	O	O
lower	lower	O	O	O	O
extremities	extremities	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
infusion	infusion	O	O	O	O
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
plasmacytoma	plasmacytoma	O	O	OTHERS	I
.	.	O	O	O	O

He	he	O	O	O	O
was	was	O	O	O	O
awake	awake	O	O	O	O
,	,	O	O	O	O
revealed	revealed	O	O	O	O
no	no	O	O	O	O
changes	changes	O	O	O	O
of	of	O	O	O	O
mental	mental	O	O	O	O
status	status	O	O	O	O
and	and	O	O	O	O
at	at	O	O	O	O
rest	rest	O	O	O	O
there	there	O	O	O	O
were	were	O	O	O	O
no	no	O	O	O	O
further	further	O	O	O	O
motor	motor	O	O	O	O
symptoms	symptoms	O	O	O	O
.	.	O	O	O	O

Cranial	cranial	O	O	O	O
magnetic	magnetic	O	O	O	O
resonance	resonance	O	O	O	O
imaging	imaging	O	O	O	O
and	and	O	O	O	O
extensive	extensive	O	O	O	O
laboratory	laboratory	O	O	O	O
studies	studies	O	O	O	O
failed	failed	O	O	O	O
to	to	O	O	O	O
reveal	reveal	O	O	O	O
structural	structural	O	O	OTHERS	I
lesions	lesions	O	O	OTHERS	I
of	of	O	O	OTHERS	I
the	the	O	O	OTHERS	I
brain	brain	O	O	OTHERS	I
and	and	O	O	O	O
metabolic	metabolic	O	O	OTHERS	I
abnormalities	abnormalities	O	O	OTHERS	I
.	.	O	O	O	O

An	an	O	O	O	O
electroencephalogram	electroencephalogram	O	O	O	O
showed	showed	O	O	O	O
continuous	continuous	O	O	O	O
,	,	O	O	O	O
generalized	generalized	O	O	O	O
irregular	irregular	O	O	O	O
slowing	slowing	O	O	O	O
with	with	O	O	O	O
admixed	admixed	O	O	O	O
periodic	periodic	O	O	O	O
triphasic	triphasic	O	O	O	O
waves	waves	O	O	O	O
indicating	indicating	O	O	O	O
symptomatic	symptomatic	O	O	O	O
encephalopathy	encephalopathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
discontinued	discontinued	O	O	O	O
and	and	O	O	O	O
within	within	O	O	O	O
12	12	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
the	the	O	O	O	O
asterixis	asterixis	O	DISEASE	OTHERS	I
resolved	resolved	O	O	O	O
completely	completely	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
described	described	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
presence	presence	O	O	O	O
of	of	O	O	O	O
asterixis	asterixis	O	DISEASE	OTHERS	I
during	during	O	O	O	O
infusion	infusion	O	O	O	O
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
normal	normal	O	O	O	O
laboratory	laboratory	O	O	O	O
findings	findings	O	O	O	O
and	and	O	O	O	O
imaging	imaging	O	O	O	O
studies	studies	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
resolution	resolution	O	O	O	O
of	of	O	O	O	O
symptoms	symptoms	O	O	O	O
following	following	O	O	O	O
the	the	O	O	O	O
discontinuation	discontinuation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
negative	negative	O	O	O	O
myoclonus	myoclonus	O	DISEASE	OTHERS	I
is	is	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
IFX	ifx	O	O	OTHERS	I
.	.	O	O	O	O

